arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Global Pharmaceutical and Biotechnology Conference 2016

Transformation Strategies for a Value Driven World

London |  - 
Speakers include:
Andrew  Witty

Andrew Witty


 Olivier  Brandicourt

Olivier Brandicourt


 Lars Rebien  Sørensen

Lars Rebien Sørensen

Novo Nordisk


The FT Global Pharmaceutical and Biotechnology Conference, now in its 34th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in an industry in flux.

Transformational shifts in healthcare markets herald challenges as well as opportunities ahead for the global life science industry. Considerations around value and outcomes of drug and other medical interventions are becoming a part of the fabric of the industry as health technology assessment and integrated care models gain traction in a growing number of markets. Some 15 years after the sequencing of the human genome, renewed efforts are under way to ensure that the vision of personalised healthcare becomes a reality, whilst the pace of digital health innovations continues, offering both new opportunities to engage with patients and also new competitors in the shape of data savvy companies increasingly encroaching in pharma’s traditional space. The new reality for life sciences companies is a blurring of traditional industry boundaries, and a need to collaborate at an unprecedented rate.

fallback Add to my Calendar 11/15/2016 08:00:0011/16/2016 12:45:00trueFT Global Pharmaceutical and Biotechnology Conference 2016The FT Global Pharmaceutical and Biotechnology Conference, now in its 34th successful year brings together life science companies, their health industry counterparts and emerging new industry entrants to review the key challenges facing the industry, and the business models and transformation strategies that will be needed to survive and thrive in an industry in flux.Transformational shifts in healthcare markets herald challenges as well as opportunities ahead for the global life science industry. Considerations around value and outcomes of drug and other medical interventions are becoming a part of the fabric of the industry as health technology assessment and integrated care models gain traction in a growing number of markets. Some 15 years after the sequencing of the human genome, renewed efforts are under way to ensure that the vision of personalised healthcare becomes a reality, whilst the pace of digital health innovations continues, offering both new opportunities to engage with patients and also new competitors in the shape of data savvy companies increasingly encroaching in pharma’s traditional space. The new reality for life sciences companies is a blurring of traditional industry boundaries, and a need to collaborate at an unprecedented rate.pharmaFT-Global-Pharmaceutical-and-Biotechnology-Conference-201613196810f4bd3a96b23c5bbcf058a873MM/DD/YYYY


“This FT conference has become an annual leadership forum on the international stage, it’s a really important event for London and the UK.”

The Rt Hon George FreemanMinister for Life Sciences UK


“The FT is always at the centre of what goes on in the industry. It’s a great source for all kinds of information and this conference for me is a great way to keep up with the trends and figure out what’s going on in the industry.”

Dr Flemming Ornskov, Chief Executive Officer, Shire


“The FT conference is one of the most important conferences in Europe and it’s a no-brainer that people participate in this event.”

Stefan Oschmann, Vice Chairman of the Executive Board & Deputy CEO, Merck


Speakers (44)

Andrew  Witty

Andrew Witty

Chief Executive Officer

Andrew became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined Glaxo in 1985 and held a variety of Sales and Marketing roles in the UK and abroad including South Africa, The USA and Singapore where he was Senior Vice President, Asia Pacific. In 2003 Andrew became President of GSK Europe, and joined GSK’s Corporate Executive Team.

Andrew has a Joint Honours BA in Economics from the University of Nottingham.

 Olivier  Brandicourt

Olivier Brandicourt

Chief Executive Officer

A physician by training, Olivier Brandicourt joined Sanofi in 2015 after serving as Chief Executive Officer of Bayer Healthcare since 2013. Prior to Bayer, Mr Brandicourt worked at Pfizer for 13 years, where he most recently served as President and General Manager of the Emerging Markets and Established Products business units. Mr Brandicourt started his career as a Medical Director for the Region Africa at Warner- Lambert/Parke-Davis, where he held other senior positions before being appointed General Manager of Canada. He also spent eight years with the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris. He is a member of the Board of Management of PhRMA, as well as a member of the Council of IFPMA. He is also an Honorary Member of the Royal College of Physicians in London and a board member of the Children’s Aid Society in New York. Mr Brandicourt studied medicine in Paris where he specialised in Infectious Diseases and Tropical Medicine.

 Lars Rebien  Sørensen

Lars Rebien Sørensen

Chief Executive Officer
Novo Nordisk

Lars Rebien Sørensen was appointed President and Chief Executive Officer of Novo Nordisk in November 2000. He is also Vice Chairman of the board of Carlsberg A/S, Denmark. Mr Sørensen joined Novo Nordisk's Enzymes Marketing in 1982. Over the years, he has completed several overseas postings, including in the Middle East and the US. Mr Sørensen was appointed a member of Corporate Management in May 1994, and in December 1994 he was given special responsibility within Corporate Management for Health Care. Mr Sørensen has an MSc in Forestry from the Royal Veterinary and Agricultural University, Denmark (now the Faculty of Science of the University of Copenhagen) from 1981 and a BSc in International Economics from the Copenhagen Business School from 1983. Mr Sørensen received the French award Chevalier de l'Ordre National de la Légion d'Honneur in 2005. In October 2007, Mr Sørensen became an adjunct professor at the Faculty of Life Sciences of the University of Copenhagen.

David Prior of Brampton

David Prior of Brampton

Parliamentary Under-Secretary
of State for Heath

Lord Prior of Brampton was appointed Parliamentary Under-Secretary of State for Heath in July 2016. His main ministerial responsibilities are life sciences, the pharmaceutical industry, NHS Estates and procurement. Before this, he was Minister for NHS Productivity. Lord Prior was previously the Chairman of the Care Quality Commission from 2013-2015. He also served as Chairman of the NHS Workforce Race Equality Standard Strategic Advisory Group, as well as Adviser to the Health Authority of Abu Dhabi.  From 2002 to 2013, he was Chairman of the Norfolk and Norwich University Hospital. Lord Prior was MP for North Norfolk (1997-2001) and went on to be Deputy Chairman and CEO of the Conservative Party.  He also served on the Commons Select Committee for Trade and Industry. Lord Prior’s career also spans a number of years working in industry and businesses. He spent 15 years working as a Senior Executive within British Steel, becoming Commercial Director and a Member of the Executive Committee and subsequently managed a number of private companies, mainly in manufacturing and engineering. He also worked for four years as an Associate with Lehman Brothers and Lazard Freres, principally in New York, but also London and Tokyo. Lord Prior graduated from Cambridge University with an MA in Law and qualified as a Barrister in 1976.   

Neil  Woodford CBE

Neil Woodford CBE

Head of Investment
Woodford Investment Management

Neil Woodford began his career with the Dominion Insurance Company having graduated with a degree in Economics and Agricultural Economics from the University of Exeter in 1981. He pursued postgraduate studies in Finance at the London Business School during the mid-1980s before joining Eagle Star as a fund manager in 1987. In 1988, Mr Woodford moved to Henley-based fund manager Perpetual (now Invesco Perpetual), where he forged a formidable reputation running two of the UK’s biggest and most successful retail funds – Invesco Perpetual Income and Invesco Perpetual High Income. In April 2014, he left Invesco Perpetual to set up Woodford Investment Management LLP, where he is Head of Investment. He is the lead fund manager on the firm’s flagship retail fund the £8.54bn CF Woodford Equity Income fund, which raised a record £1.6bn during a two-and-a-half week launch offer period in June 2014. He also manages Woodford Patient Capital Trust, the £800m investment trust launched in April 2015 that invests predominantly in early-stage and early-growth businesses. Mr Woodford was appointed Commander of the Order of the British Empire (CBE) for services to the economy in the 2013 Queen’s Birthday Honours.

David Redfern

David Redfern

Chief Strategy Officer

David Redfern was appointed Chief Strategy Officer of GSK in May 2008.   He is a member of the Corporate Executive Team and reports to the CEO. Mr Redfern is also Chairman of ViiV Healthcare Ltd.   ViiV was created in 2010 and is a joint venture between GSK, Pfizer and Shionogi and focuses specifically on the research, development and commercialisation of medicines to treat HIV.  In February 2015, Mr Redfern was appointed a non–executive director of Aspen Pharmacare Holdings Ltd., a South African listed healthcare company. Previously, he was responsible for the leadership of GSK’s business in Northern Europe from 2005-2008 and Central Europe from 2002-2005.  He joined Glaxo in 1994 in finance and progressed through a series of finance roles before becoming Finance Director of the European business in 1999.  Prior to Glaxo, Mr Redfern worked for PWC in London, Zambia and Paris.   

Albert Bourla

Albert Bourla

Group President
Pfizer Innovative Health

Albert Bourla is the Group President of Pfizer Innovative Health at Pfizer Inc., and is a member of the Company’s Executive Leadership Team.  Pfizer Innovative Health includes six business groups: Consumer Healthcare, Inflammation & Immunology, Internal Medicine (neuroscience and pain, and cardiovascular and metabolic), Oncology, Rare Disease and Vaccines It also includes Pfizer’s Global Health and Value organization, which is focused on demonstrating the value of innovation and supports access to Pfizer medicines and vaccines. Mr Bourla has more than twenty years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Before assuming his current role, he was the Group President of Pfizer’s Global Vaccines, Oncology and Consumer Healthcare Business. Previously, he was President and General Manager of Pfizer’s Established Products Business, where he led the development and implementation of strategies and tactics related to Pfizer’s off-patent portfolio. Mr Bourla joined Pfizer’s Animal Health Division in 1993 as Technical Director of Greece. He held positions of increasing responsibility across Europe before moving to Pfizer Global Headquarters in New York in 2001 to assume the role of US Group Marketing Director for Animal Health. In 2004, he became Vice President of Business Development and New Products Marketing; supervising Pfizer Animal Health global licensing and acquisition activities, as well as the unit’s R&D portfolio. In 2006, he was appointed Area President of Europe, Africa and Middle East and in 2009, he assumed additional responsibilities for Asia and Pacific. Mr Bourla is a Doctor of Veterinary Medicine and holds a PhD in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. 

Andrew Jack

Andrew Jack

Head of Curated Content
Financial Times

Andrew Jack has worked as a journalist for the Financial Times since 1990. He currently runs the curated content team, which picks the best news and analysis from the FT and the rest of the web. He was previously Deputy Editor of the Analysis section, Pharmaceuticals Correspondent, Moscow Bureau Chief, Paris Correspondent, Financial Correspondent, general reporter and corporate reporter. He is author of the books Inside Putin’s Russia and The French Exception, as well as numerous specialist reports, and has appeared on the BBC and other media outlets.

Luc  Debruyne

Luc Debruyne

President, Global Vaccines
GSK Vaccines

As President of GSK’s global vaccines business, Luc Debruyne oversees a world-leading enterprise delivering vaccine to 90% of the world’s countries and more than £3 billion in annual revenue to GSK. He is a member of GSK’s Corporate Executive Team. Mr Debruyne joined GSK in 1991 and has held a variety of roles with increasing responsibility since then, most recently as Senior Vice President for Europe. He holds a Master’s degree in Physical Education from the University of Leuven, Belgium, where he received an Alumni Award.

Adam  Plich

Adam Plich

VP, Head of Pricing & Market Access Europe
Teva Pharmaceuticals

A pharmacist by training, Adam Plich has 10 years of experience in pricing, market access and health economics in the pharmaceutical industry. Since 2012 he has been leading the pricing and market access team and activities at TEVA Europe for specialty, biosimilar and generic medicines. He is also a chair of the Health Technology Assessment (HTA) working group at the European Generics Association (EGA) where – together with other companies – he develops and advocates for the tailored use of HTA in the assessment of the value added medicines. Medicines that are based on known molecules which deliver considerable improvements for patients, payers and/or healthcare professionals. Mr Plich is a frequent conference speaker and a lecturer of pricing and market access at the post­graduate studies at the University of Aix Marseille, France and the University of Economics Poznan, Poland. He has authored and contributed to numerous health economic and health policy posters and publications.

Ron Kuerbitz

Ron Kuerbitz

Fresenius Medical Care North America

Ron Kuerbitz was appointed Chief Executive Officer of Fresenius Medical Care North America (FMCNA) in January 2013 after holding executive positions in operations and administration within the organisation for more than 15 years. Under his leadership, FMCNA has evolved to become the country’s leading provider of integrated health care services for renal patients, and its capabilities have expanded into hospitalist medicine, cardiovascular care and programs designed to flourish in a consumer and value driven health care system.

From 2010-2013 Mr Kuerbitz served as Chairman of Kidney Care Partners, a coalition of industry advocates, where he introduced and garnered support for a bundled payment methodology from Medicare for dialysis services, which has yielded significant improvements in the quality and efficiency of care. A graduate of Yale Law School, Mr Kuerbitz is also a member of the Management Board of Fresenius Medical Care AG & Co. KGaA, the parent company of FMCNA based in Frankfurt, Germany.

Lisa Urquhart

Lisa Urquhart

EP Vantage

Lisa Urquhart is editor of EP Vantage, a leading online news and analysis service covering the pharma, biotech and medtech industries. A journalist with more than a decade of industry experience, Lisa joined EP Vantage from the Financial Times, where she held a variety of positions, including biotechnology correspondent.  Lisa is an active contributor to industry panels and articles and has commented on the pharmaceutical industry on both television and radio, focusing on business models, M&A and R&D strategies and innovation. In 2011 she was part of the EP Vantage team that won European Mediscience Commentator of the Year.

Steve  Wooding

Steve Wooding

Head, Global Commercial and Market Access Strategy

Steve Wooding is the Head, Global Commercial Strategy/ Market Access Organisation at Janssen, a position he assumed in June 2015 In this role, Dr Wooding leads an organisation with primary responsibility for the ongoing evolution and stewardship of Janssen’s vision and global strategy to drive transformational medical innovation and position Janssen as a global pharmaceuticals leader.  Dr Wooding and his team help identify and adapt to market challenges, develop new strategies for growth and in partnership with R&D colleagues and the commercial operating regions, seize opportunities to continue to transform the lives of patients around the world.

Dr Wooding has held senior commercial and market access leadership roles around the world joining the industry from the NHS where he initially focused on R&D and Medical Affairs.

Greg  Rossi

Greg Rossi

Director, Oncology, Business Unit Director
AstraZeneca UK Marketing Company

Greg Rossi is Director Oncology, Business Unit Director of AstraZeneca UK Marketing Company. He also has overall responsibility for Pricing and Market Access for all AstraZeneca products in the UK. Mr Rossi joined AstraZeneca in 2011 as Vice President, Payer and Real World Evidence with global responsibility for coverage and reimbursement submissions and real world evidence (outcomes) studies. Prior to joining AstraZeneca, Dr Rossi was with Genentech Inc/Roche Pharmaceuticals, from 2007, where he was responsible for outcomes research, health economics and global pricing. These responsibilities included providing input into the design of phase 2, 3 and 4 studies, conducting observational research studies, development pricing policies as well as the generation of Health Technology/Reimbursement Dossiers for coverage and reimbursement submissions. Between 1996 and 2007 Dr Rossi was at Amgen Inc, where he held a number of roles in regulatory affairs, clinical development and global product strategy. He was involved in the clinical development and registration of a number of oncology products. He is author of over 25 clinical research manuscripts and numerous abstracts. Dr Rossi received his Doctorate in Molecular Biology and Protein Chemistry from the University College London (UCL) in 1993. 

Clare Moloney

Clare Moloney

Clinical Strategy Director Europe
Atlantis Healthcare

Clare Moloney has been part of the Atlantis Healthcare team since 2010 and is Clinical Strategy Director for Europe. She manages the Health Psychology team who specialise in the field of health behaviour change and is instrumental in developing both the academic and applied intervention strategy for Atlantis. Her role involves overseeing the design and delivery of self-management programs for people living with chronic conditions. Alongside her work at Atlantis Healthcare, ms Moloney continues to work as a consultant psychologist, providing academic lectures and seminars on health psychology, behaviour change theory and intervention design. She also delivers training on core health psychology principles to healthcare professionals, nurses and pharmacists.

Eliot Forster

Eliot Forster

CEO, Immunicore and Chairman

Eliot Forster joined Immunocore as Chief Executive Officer in January 2015.  He has around 25 years of experience in the pharmaceutical and biotechnology industry.  Dr Forster previously served as Chief Executive Officer of Creabilis, from 2010, and prior to that was Chief Executive Officer of US biotechnology company, Solace Pharmaceuticals Inc.  His other previous roles include senior Development roles at Pfizer and clinical research roles at GlaxoSmithKline.  Dr Forster is Chairman of the MedCity project that aims to grow a world-leading life sciences cluster in the South Eeast of England.  He holds a PhD from Liverpool University and an MBA from Henley Management College.

Mike Standing

Mike Standing

EMEA Life Sciences and Healthcare Lead

Mike Standing is the Life Sciences and Healthcare industry leader for Deloitte for EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare organisations in Europe, US and China for over 20 years, focusing on commercial strategy, operations and R&D productivity. In addition, he is currently leading major programmes to understand how real world evidence can transform health outcomes and productivity. He also advises governments on building healthcare clusters and is a member of the UK's Global Medical Excellence Cluster (GMEC) Advisory Board. Prior to joining Deloitte, Mr Standing was Co-Head of Life Sciences for the Monitor Group and Global Head of Capgemini's Life Sciences business. He is a graduate of Durham and Cambridge Universities and is based in London.

Philipp Gutzwiller

Philipp Gutzwiller

Global Head Healthcare
Lloyds Bank

Philipp Gutzwiller is leading the coverage of global corporate clients in the healthcare sector for Lloyds Bank. He has accumulated over 15 years as a corporate finance advisor and banker to the pharmaceutical industry. Before joining Lloyds Bank, Philipp worked for both bulge-bracket and boutique investment banks with a focus on M&A advisory in the broader healthcare industry. He started his career in the Corporate Finance Division of Roche as a financial controller and later worked in the firm’s corporate M&A department. Mr Gutzwiller holds a Master’s Degree in Finance and Economics from the University of Basel, Switzerland.

Daniel Mahony

Daniel Mahony

Polar Capital

Daniel Mahony joined Polar Capital to set up the healthcare team in 2007. He has more than 15 years’ investment experience in the healthcare sector, with over six years as a Portfolio Manager and nine years as a sell-side analyst. Prior to joining Polar Capital, he led the European healthcare research team at Morgan Stanley, covering the European biotechnology, medical technology and healthcare services sectors. He also previously worked in New York for ING Barings Furman Selz following the US biotechnology sector. Before working in the investment field, Mr Mahony worked as a research scientist for seven years with the majority of his time at Schering Plough Corporation in California. He received his PhD from Cambridge University in 1995 and a first class honours degree in biochemistry from Oxford University in 1991.

Chris Silva

Chris Silva

Chief Executive Officer
Allied Minds

Chris Silva is the Chief Executive Officer of Allied Minds, a US. science and technology development and commercialisation company. Operating since 2006, the company forms, funds, manages and builds products and businesses based on innovative technologies developed at leading US universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses with capital, management and shared services. The company has formed over 25 majority-owned subsidiary businesses to date and Mr Silva serves on the boards of many of the firm’s portfolio companies. Prior to joining Allied Minds, Mr Silva was a Partner at JSA Partners, an M&A firm. He was also a member of AT Kearney’s Aerospace Aviation & Defense Practice and GRC Intl, a Dept. of Defense and Intelligence Agency contractor. Mr Silva served in the US Air Force and Intelligence Community and holds a BA from Tufts and an MBA.

Hervé  Hoppenot

Hervé Hoppenot

President and Chief Executive Officer
Incyte Corp

Hervé Hoppenot joined Incyte in 2014 as President and Chief Executive Office, and was appointed Chairman of the Board of Directors in 2015. Prior to joining Incyte, Mr Hoppenot was the President of Novartis Oncology, where he was responsible for translational medicine, development, approval and commercialisation, which included $11bn in global sales, the largest oncology pipeline in the industry, and a workforce of 8,000 employees in 50 countries. Mr Hoppenot joined Novartis in 2003 and, in addition to his role as President, served as Chief Commercial Officer, Head of Global Product Strategy & Scientific Development, and Senior Vice President, Head of Global Marketing. He started his career in 1983 with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including Vice President of Oncology and Head of the US Oncology business unit. Mr Hoppenot holds a Diploma from ESSEC Business School.

Nooman  Haque

Nooman Haque

Managing Director, Life Science & Healthcare
Silicon Valley Bank

Nooman Haque is the Managing Director of Life Sciences & Healthcare with Silicon Valley Bank’s UK Branch. He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. He is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector as a regular speaker and panellist, and also contributes to the BIA Finance sub-committee. He has also advised the UK Government and MedCity on financing issues within life sciences

Mr Haque joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and risk management.

He has a Bsc in psychology and Msc in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society and the Royal Economic Society.

Adityo Prakash

Adityo Prakash

Co-Founder and CEO

Adityo Prakash is co- founder Verseon – a US pharmaceutical company that has developed a computational drug discovery platform based on advancements made by the company in modelling the physics of molecular interactions and creation of methods for exploring a large number of novel chemicals as possible drug candidates. Verseon has a growing pipeline of drug programmes, which currently span anticoagulation, diabetic macular edema, and solid tumours. The anticoagulation programme, in late preclinical testing, has several chemically diverse candidates representing a new class of oral, highly selective, direct thrombin inhibitors that significantly reduce the risk of bleeding relative to new oral anticoagulants (NOACs). Prior to Verseon, Mr Prakash co-founded and led Pulsent, a company which developed ground-breaking video compression and processing technologies, now owned by Intel, and used by video streaming companies. Mr Prakash has a degree in physics from Caltech and is an inventor in over thirty patents.

Dr Hans-Georg Eichler

Dr Hans-Georg Eichler

Senior Medical Officer
European Medicines Agency (EMA)

Hans-Georg Eichler, MD, MSc, is the Senior Medical Officer at the European Medicines Agency (EMA) in the United Kingdom, where he is responsible for coordinating activities between the Agency’s scientific committees and giving advice on scientific and public health issues. Prior to joining the European Medicines Agency, Dr Eichler was at the Medical University of Vienna in Austria for 15 years. He was Vice-Rector for Research and International Relations from 2003, and Professor and Chair of the Department of Clinical Pharmacology from 1992. His other previous positions include president of the Vienna School of Clinical Research and co-chair of the Committee on Reimbursement of Drugs of the Austrian Social Security Association. His industry experience includes time spent at Ciba-Geigy Research Labs, UK, and Outcomes Research at Merck & Co, in New Jersey. In 2011, Dr Eichler was the Robert E. Wilhelm fellow at the Massachusetts Institute of Technology’s Center for International Studies, participating in a joint research project under the MIT’s NEWDIGS initiative.

Dr Eichler graduated with an MD from Vienna University Medical School and a Master of Science degree in Toxicology from the University of Surrey in Guildford, UK. He trained in internal medicine and clinical pharmacology at the Vienna University Hospital as well as at Stanford University.

Steve Cutler

Steve Cutler


Steve Cutler was appointed Chief Executive Officer of ICON plc in March, 2017, and serves on ICON’s Board of Directors. ICON is a global leader in the provision of outsourced development services to the pharmaceutical, biotechnology and medical device industries. Renowned for delivering excellence and innovation in the drug development process, ICON counts all of the world’s leading pharmaceutical and biotechnology companies amongst its customers. The company has particular expertise in helping transform pharma R&D through strategic partnerships and alliances. Dr Cutler joined ICON in 2011 as Group President, Clinical Research Services and was appointed Chief Operating Officer in January 2014, where he led ICON’s global operations, strategic customer alliances and the management of more than 460 clinical development projects from Phase IIb - IV. Dr Cutler has over 25 years of experience in the pharmaceutical and CRO industries. Prior to joining ICON, he was Chief Executive Officer of Kendle and oversaw the sale of the company to INC Research. Prior to Kendle, he held various operational and general management roles in both Quintiles and Sandoz (Novartis). Dr Cutler holds a BSc and a PhD from the University of Sydney and a Masters of Business Administration from the University of Birmingham.

Sir John  Chisholm

Sir John Chisholm

Executive Chair
Genomics England

Sir John is a Cambridge graduate who started work in the automobile industry. His career took flight when he founded CAP Scientific Ltd, which grew rapidly to become a core part of the CAP Group plc and subsequently the Sema Group plc of which he was UK Managing Director. He was then asked by the government to take on the transformation of its defence research laboratories into a commercial organisation. In due course these became an internationally successful technology services company and were floated on the LSE as QinetiQ Group plc of which Sir John became Chairman in 2006. At the same time he was asked to take the Chair of the Medical Research Council. Sir John retired from QinetiQ in February 2010. Sir John is a past president of the IET and holds a number of honorary Doctorates and Fellowships, including the Royal Academy of Engineering. He was knighted in 1999. In April 2015 he was accepted as a director of the Historic Grand Prix Cars Association.

Rudi  Pauwels

Rudi Pauwels

Chief Executive Officer

Rudi Pauwels, PhD is the Chief Executive Officer of Biocartis a company he founded in 2007. As a pharmaceutical scientist working in the 1960’s, in Belgium, Dr Pauwels belonged to the first group of HIV/AIDS researchers who, shortly following the discovery of HIV in 1983-1984, launched their efforts to find new treatments for the disease. For nearly 3 decades, Dr Pauwel’s primary focus was on the research and development of anti-HIV drugs, a number of which were approved and introduced in the clinic, generating several billion USD revenue. Dr Pauwel was also involved at this time in the development of diagnostic technologies and products that address the growing need for high precision, more personalised medicine. Dr Pauwel’s research, as well as his entrepreneurial career is driven by medical needs and his passion to advance medicine. He has a strong belief in the value of a multidisciplinary scientific, technological and clinical approach to solving key pharmaceutical and diagnostic challenges. In 2004, Dr Pauwels expanded his areas of interest into micro- and nanotechnology and went on a 3-year sabbatical at the Swiss Federal Institute of Technology-EPFL in Lausanne, Switzerland, one of the leading research centres in this emerging field. Dr Pauwels is Co- Author of more than 150 papers in peer-reviewed journals, and is the recipient of several awards for his scientific and entrepreneurial accomplishments. In 2012, he and Biocartis received the Global Technology Pioneer Award from the World Economic Forum in Davos, Switzerland. He received an Honorary Doctorate Degree from the University of Ghent in 2013. Dr Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium.

Ruth  March

Ruth March

VP and Head Personalised Healthcare & Biomarkers

Ruth March is VP and Head of Personalised Healthcare and Biomarkers at AstraZeneca. A member of the senior team leading Innovative Medicines & Early Development, Ms March is accountable for patient selection strategies and companion diagnostics to all AstraZeneca clinical drug projects, targeting medicines across therapy areas to those most likely to benefit. Ms March also leads AstraZeneca’s Centre for Genomics Research, integrating genome sequence and clinical data from 2 million patients in AstraZeneca’s clinical trials and key international partnerships to transform drug discovery and development. This initiative will sequence an unprecedented number of genomes, discover rare genomic variants with functional significance and be applied comprehensively across AstraZeneca and MedImmune’s therapeutic pipeline. Ms March led AstraZeneca’s capability build in Personalised Healthcare (PHC); achieved 12 diagnostic launches to date supporting regulatory approvals of 3 Oncology therapies; pioneered innovation in PHC science: achieved the world’s first regulatory approval based on circulating tumour DNA (IRESSA); the first companion diagnostic partnership in next generation sequencing (Illumina); the first FDA approval of a laboratory-based companion diagnostic (BRCA for LYNPARZA); and the first diagnostic launch based on both ctDNA and tissue testing (TAGRISSO, EU). Leading a function of 110 diagnostic experts and scientists, Ms March has ensured that over 80% AstraZeneca drugs are following a PHC approach, increasing R&D success rates and leading to smaller, faster clinical trials. A scientific expert with 50 publications in her field, she serves as a member of Definiens’ Supervisory Board for Tissue Phenomics delivery to Immuno-Oncology projects, focusing on companion diagnostic development and strategy.

Keith Stewart

Keith Stewart

Center for Individualized Medicine, Mayo Clinic

Keith Stewart, MB, ChB is a consultant in the Division of Hematology and Oncology, Department of Internal Medicine, Mayo Clinic, and Professor of Medicine, Mayo Clinic College of Medicine. He currently serves as the Carlson and Nelson Endowed Director of the Center for Individualized Medicine and is the Vasek and Anna Maria Polak Professor of Cancer Research. Dr. Stewart’s research focuses on individualized treatment of multiple myeloma and has published over 250 manuscripts in this field of study with 20 years of sustained national funding for a laboratory research program. As Director of the Center for Individualized Medicine at Mayo Clinic he is charged with delivering the promise of genomics to clinical practice. Dr Stewart earned his MB, ChB degree at Aberdeen University Medical School, UK, and an MBA degree at the University of Western Ontario.

Richard Barker

Richard Barker

Precision Medicine Catapult

Richard Barker is an internationally respected leader in healthcare and life sciences.

He is Director of the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances more rapidly and affordably to patients.

He was recently appointed as chair of the Precision Medicine Catapult, forging a national strategy in this rapidly developing field.

He is also chairman of the South London Academic Health Science Network, accelerating innovation in this region of the NHS, and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease. He is a board member of Celgene, a major US-based bio-therapeutics company and of iCo Therapeutics, a Canadian bioscience company.

His 25-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. Most recently he was Director General of the Association of the British Pharmaceutical Industry, Board member of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent).  

As a Co-Founder of Life Sciences UK, member of the NHS Stakeholder Forum, Vice-Chair of the UK Clinical Trials Collaboration and in many other roles, he has advised successive UK governments on healthcare issues, especially those relating to developing, valuing and using new healthcare technologies.

His past leadership roles include head of McKinsey’s European healthcare practice, General Manager of Healthcare Solutions for IBM and Chief Executive of Chiron Diagnostics. He was also Chairman and Chief Executive of Molecular Staging, a US bioscience company, now part of Qiagen. He therefore has experience in leading and advising a wide range of high-technology companies.

His book on the future of healthcare 2030 - The Future of Medicine: Avoiding a Medical Meltdow ’ is published by Oxford University Press. 

Jayasree Iyer

Jayasree Iyer

Executive Director
Access to Medicine Foundation

Jayasree K. Iyer leads the strategic direction, research programmes and stakeholder outreach of the Access to Medicine Foundation. She spearheads the Foundation’s discussions with companies, governments and with over 50 key pharmaceutical industry investors, among others in the area of access to medicine. She also writes on platforms such as the Stanford Social Innovation Review and is regularly quoted in media outlets to include the Financial Times regarding access to medicine initiatives in the pharma industry. She is responsible for the Access to Medicine Index, the upcoming Access to Vaccines Index and the various thematic studies into priority health topics published by the Foundation. An independent third-party evaluation has confirmed that the Index serves both as a catalyst and an inspiration for pharmaceutical companies’ access-to- medicine activities.

Samantha Du

Samantha Du

Chairman and Chief Executive Officer
Zai Lab Limited

Dr Samantha Du is a leading figure and seasoned entrepreneur of China's biotech industry. She is the Founder, Chairman and CEO of ZAI Lab, a premier innovative biopharmaceutical company in China.  Dr Du is recognized for her wide influence on healthcare policies and for her work with various government bodies in China.  She served on numerous government committees including the Planning Committee of the 12th Five Year State Key Healthcare Initiatives. She was a founding Chair of Shanghai Innovation Committee and a founding member and Chairwoman of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Innovation Drug Investment Committee.  Dr  Du has received numerous awards and recognitions.  She was voted 2015 Fierce Biotech top 12 women in biopharma. She was also a recipient of Shanghai’s 2010 Magnolia award (an honorable citizenship award) and recipient of Shanghai’s thousand talent program. She was recogniSed as 2015 R&D Leader of the Year by Bayhelix and China Entrepreneur of the Year in 2008. She has been featured in many magazines and newspapers around the world, including the Wall Street Journal and Forbes for her significant contribution to China’s life science industry, and was on the cover of Forbes Asia in 2007.

Laurie Olson

Laurie Olson

Executive Vice President - Strategy, Portfolio and Commercial Operations

Laurie Olson is Executive Vice President of Strategy, Portfolio and Commercial Operations of Pfizer. She is responsible for overseeing the shaping of Pfizer’s longer-term strategy, supporting the execution for Pfizer’s commercial objectives, and providing portfolio advisory functions to guide R&D investment decisions. Ms Olson is a member of Pfizer’s Executive Leadership Team and also a member of the Portfolio Strategy Investment Committee, which oversees decisions regarding enterprise portfolio investment and advancement. Ms Olson joined Pfizer in 1987 as an Analyst in the company’s Marketing Research organisation. She has since held both US and global leadership roles in marketing, commercial development, strategy, analytics and operations. In her most recent role as Senior Vice President, Portfolio Management and Analytics, she served on an executive task force that successfully redesigned Pfizer’s R&D organisation to strengthen its pipeline and improve efficiency. In 2011, Corporate Strategy was added to her responsibilities. In addition to her daily responsibilities, she is the executive sponsor of Pfizer’s global Lesbian, Gay, Bisexual, and Transgender Colleague Council and serves on the company’s worldwide Diversity Leadership Council. Ms Olson earned a Bachelor of Science degree in Economics from the State University of New York at Stony Brook and an MBA in Marketing from Hofstra University.

Emmanuel  Blin

Emmanuel Blin

Chief Strategy Officer
Bristol-Myers Squibb

Emmanuel Blinis Chief Strategy Officer of Bristol-Myers Squibb. In this role, he leads Strategic Planning, Oncology Commercialisation, Specialty Portfolio Strategy, Policy and Government Affairs, and Business Model Innovation.

Mr Blin joined Bristol-Myers Squibb in 1997 as Director, Sales Force Effectiveness, UPSA France. In 1999, he became Director, Operational Effectiveness, International Medicines in the US. In 2001, he was named Regional Business Director, Cardiovascular, South France. In 2003, he relocated to Budapest, as General Manager, Hungary-Romania-Bulgaria. In this role, he launched several key products and managed EU accession of these three markets.

In 2006, he was promoted to Regional General Manager, Austria and Central Europe, where he transformed the company strategy and footprint in this region. In 2007, Mr Blin returned to France and served as Vice President, Primary Care France. In June 2008, he was promoted to Vice President, Commercial Operations France, and managed all commercial operations for the French affiliate. In 2010, he assumed the role of President and General Manager of Japan, where he doubled sales and the Bristol-Myers Squibb footprint in this major market. In 2013, he was named head of Worldwide Commercialisation, leading the company’s commercial portfolio and brand strategies. In 2015 he was named Head of Commercialisation, Policy and Operations and co-lead of the commercial organiSation.

Prior to joining Bristol-Myers Squibb, Mr Blin was with Sanofi Turkey and then worked as a Senior consultant for Gemini Consulting. He is a graduate of ESSEC Business School in Paris and has completed the General Management Program of INSEAD-CEDEP.

View Emmanuel's profile on LinkedIn >>

Michel Vounatsos

Michel Vounatsos

Executive Vice President and Chief Commercial Officer

Michel Vounatsos is Executive Vice President and Chief Commercial Officer at Biogen. He brings extensive global biopharmaceutical experience and a track record of innovative stakeholder engagement to his leadership of the company’s commercial organisation. Mr Vounatsos joined Biogen in 2016 after a 20 career at Merck, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world's largest governments. He previously held leadership positions across Europe and in China for Merck. Earlier in his career, Mr Vounatsos held management positions at Ciba-Geigy.Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.

Jessica Federer.

Jessica Federer.

Hugo Health

Recognized as one of the top 100 global Chief Digital Officers (CDOs), a "Power-Lady" of the German economy, and a leading Health Tech Influencer, Jessica Federer is adept at translating digital developments into meaningful advancements for both business and society. After serving as the Chief Digital Officer for Bayer, Jessica is now an advisor for health and technology companies, and a Venture Affiliate Partner at Boston Millennia Partners. Prior to leading digital at Bayer, Federer held positions in Global Regulatory Affairs, Market Access, Communications and Public Affairs. She also served on the United Nations m-Powering Development Advisory Board for the Agency for Information and Communications Technology (ITU). Jessica began her public health career as an analyst at the Agency for Healthcare Research and Quality in the US Department of Health and Human Services. She earned a Bachelor of Science degree from the George Washington University, and a Master of Public Health from Yale.

Randall Moore

Randall Moore

Mercy Virtual

Dr Randall Moore is President of Mercy Virtual, a healthcare organisation pioneering a new model of care using the power and potential of telemedicine to expand access and improve outcomes, while reducing costs. Dr Moore’s experience includes more than 30 years working as both an academic clinical physician as well as a business executive. Before joining Mercy, Dr Moore focused on the development and implementation of transformational health care models through his consulting firm. Working in major health care systems such as Intermountain Health, Ascension Health and Presence Health, his work focused on evolving from traditional fee for service to optimizing value of population health. As CEO of Telecare, the company developed innovative solutions to enable health care teams to extend care beyond the walls of the hospital and clinic environment. By identifying the needs of the 5% of the population who use as much as 50% of all health care resources, he and his team were able to show how a telemedicine-enabled care model delivers rapid gains in team efficiency, effectiveness and most importantly, improved outcomes and quality of life for patients. Previously, Dr Moore served on the board of an 800,000 member managed Medicaid/Medicare health plan, including chairman of the Compensation and Medicare Quality Committees. Dr Moore graduated with Alpha Omega Alpha honours from Johns Hopkins School of Medicine, before completing his training in internal medicine at the University of Minnesota, where he was chosen Chief Resident, and served on the faculty for nine years. His education also includes study at the University of London, graduate studies at the University of Minnesota, and earning his MBA from the Kellogg Graduate School or Management at Northwestern University.

Stefani Klaskow

Stefani Klaskow

Head of Industry, Healthcare

Stefani Klaskow leads Google’s healthcare advertising sales team to provide digital advertising solutions for the world’s largest pharmaceutical companies. Being part of the group for nearly a decade she has been instrumental in leading pharmaceutical organisations in thinking through their digital strategies and developing their digital footprints. Ms Klaskow came to Google from Crain Communications, where she was a Regional Sales Manager for the Modern Healthcare and Modern Physician properties responsible for creating large scale cross-platform advertising programs. Prior to her work at Crain, Ms Klaskow was a Senior Account Executive at Clear Channel Communications where she sold and managed advertising programs across six of New York City's top radio stations Ms Klaskow is a graduate of Union College and holds a Master's Degree in Social Work from the University of Pennsylvania. 

Dr Harpreet  Sood

Dr Harpreet Sood

Senior Fellow, Chair and Chief Executive's Office
NHS England

Dr Harpreet Sood is currently Associate Chief Clinical Information Officer (CCIO) at NHS England and is also a practicing NHS Doctor. He was formerly Senior Fellow to the CEO of NHS England where his portfolio of work included healthcare prevention and innovation and health technology policy. In healthcare prevention, Dr Sood was involved with the launch and implementation of the NHS Diabetes Prevention Programme. In terms of innovation and technology policy, Dr Sood  led on the Wachter Review, which has focused on digitising secondary care, developing digital health ecosystems and building informatics capabilities. Additionally, his work has involved designing policy for the reimbursement of innovation through a national tariff. In his new role as Associate CCIO at NHS England, Dr Sood will drive forward and implement the recommendations from the Wachter Review, develop the NHS Digital Academy as well as the digitisation of the diabetes prevention programme.

Prior to NHS England, Dr Sood was a Deland Fellow at Brigham and Women's Hospital in Boston where he focused on diffusing innovation through complex organisations with the launch of the iHub, service care redesign and researching the impact of health information technology on healthcare. Whilst in Boston, Dr Sood also co-founded a digital health start-up in paediatric asthma adherence, which was funded by Harvard Medical School.

Dr Sood trained as a clinical doctor at King’s College London and Imperial College Business School. He also has a Masters in Public Health (MPH) from Harvard University where he was a Carson Scholar and recently completed an executive education programme on ‘Innovating Health for Tomorrow’ at INSEAD BusinessSchool.

Anne Marieke  Ezendam

Anne Marieke Ezendam

Senior Equity Portfolio Manager
Amundi Asset Management

Anne-Marieke Ezendam joined the Global Equity team of Amundi Asset Management in January 2014. Previous positions have included Global Senior Healthcare Analyst, ING Investment Management (2011-2013), Managing Director, Market Specialist at Cross Current Research, LLC (2010-2011), Director, Equity Fund Management at Credit Suisse Asset Management, UK (2007-2009), Global Healthcare Analyst and Portfolio Manager, Threadneedle Asset Management (2002-2007), and Healthcare Analyst and Proprietary Trader, Gulf International Bank UK Limited (1997-2001). She started her career as a Medical Sales Representative at Roche Nederland BV and 3M Pharmaceuticals in the Netherlands. Ms Ezendam graduated in Biology, with Specialisation in Medicine from the University of Utrecht.

Habil  Khorakiwala

Habil Khorakiwala

Founder, Chairman and Group CEO

Habil Khorakiwala, is the Founder-Chairman of Wockhardt Group. An alumnus of Purdue University and Harvard Business School, Dr Khorakiwala has successfully led Wockhardt to become a major global healthcare company with a strong presence in USA, UK and other EU countries. His pursuance of scientific excellence has enabled the organisation to take a lead in the discovery of next generation antibiotics. The FDA have accorded breakthrough QIDP status for five of Wockhardt’s novel antibiotics. In addition to his position at Wockhart, Dr Khorakiwala is Chancellor of Jamia Hamdard University and the Chairman of the Board of Governors at the Centre for Organisation & Development, a non-profit scientific and industrial research organisation and doctoral research centre.

Dr Khorakiwala has also served as Past President of Federation of Indian Chambers of Commerce and Industry (FICCI). The Purdue University bestowed on Dr Khorikawala the prestigious title of ‘Distinguished Alumnus’ for his significant contribution to the pharmacy profession and honoured him with their highest recognition, the ‘Honorary Doctorate’ in 2010. Amongst the many other awards Dr Khoakiwala has received are the Shiromani Vikas Award for his ‘Outstanding and Inspiring Contribution towards National Development’ at the hands of Mother Teresa (1992); ‘Lifetime Achievement Award’ by Indian Express Group (2006); ‘Entrepreneur of the Year’ award by UK Trade and Investment (2008).

Isabel   Torres

Isabel Torres

Global Head of Access to Medicines
Takeda Pharmaceuticals

Isabel Torres is Global Head of Access to Medicines with Takeda Pharmaceuticals. Since joining Takeda in May 2015, she has been instrumental to the inception, development and launch of Takeda’s new Access to Medicines strategy. In that time, she has worked closely with healthcare professionals, experts, governments, and private and public partners to devise and implement a strategy designed to have the biggest possible impact on patients, focusing on countries with less-developed healthcare systems, where Takeda’s core therapeutic areas can make the biggest difference. Ms Torres has nearly 20 years’ experience in the pharmaceuticals industry. After six years at Merck Pharmaceuticals, where she began her career, Ms Torres joined Sanofi to oversee the development and implementation of its Access to Medicines programme. As part of this, she worked closely with the World Health Organization, along with governments across Africa, South-east Asia and Brazil, to develop sustainable solutions to pandemics for patients most in need. During her 11 years at Sanofi, Ms Torres was also central to the development of the company’s Worldwide Compliance Programme, the CV/IM portfolio strategy and a new Medical Affairs Programme across Asia.

Anant  Jani

Anant Jani

Honorary Research Fellow and Consultant
University of Oxford, NHS Right Care

Anant Jani is a Research Fellow in the Value Based Healthcare programme at the University of Oxford, where he leads research programmes aimed at identifying how key players in healthcare can increase value by increasing patient involvement, building outcomes-based healthcare systems, policy change and innovations (clinical, basic science, diagnostics, IT). Dr Jani’s experience in healthcare started with his work with Sir Muir Gray in the NHS England Right Care program, for which he still consults, where he helped localities across England design and implement high value Outcomes-based Healthcare Systems, including building the first national system for stroke prevention
for patients with Atrial Fibrillation, which was a joint effort with NHS England and Public Health England. Before working in healthcare, Dr Jani was a molecular immunologist studying gene regulation and epigenetics in B and T cells. He completed his undergraduate studies at Brandeis University and his doctoral studies at Yale University.

Colin Orford

Colin Orford

Senor Vice President, Drug Development Services and Consulting

Colin Orford has 27 years of experience in the pharmaceutical sector gained at GSK (SmithKline Beecham), Novartis, Quintiles and Eisai which combines development strategy with operational execution.  He has 20 years of drug development experience having led multiple R&D project teams, and has worked across all stages of the development spectrum from Phase 0 through to Phase IIIb. He has lead therapy area strategy teams in Alzheimer’s, multiple sclerosis, MDD and auto-immune disorders.    Dr Orford has been responsible for transitioning multiple molecules, targeting MDD, Sleep disorders, Schizophrenia and Alzheimer’s Disease, from Phase 0, through proof of concept and, into late phase development.  He has also led a number of Phase III teams and has been involved in several NDA and MAA submissions. Colin currently leads ICON’s Drug Development and Consulting services.


Chaired by (2)

Greg Reh

Greg Reh

Global Life Sciences & Health Care Industry Leader

Greg Reh is a Global Life Sciences & Health Care Industry Leader and the Global Life Sciences Sector Leader for Deloitte Touche Tohmatsu Limited (Deloitte). He has more than 25 years of experience in the life sciences, process manufacturing, consumer and government sectors. His consulting career has spanned such topics as technology strategy, integration solution development and implementation of emerging and disruptive technology. His clients have included multinational pharmaceutical, biotechnology and chemical manufacturing organizations where he successfully led consulting services in support of regulatory, clinical, commercialization and manufacturing operations.

Prior to his consulting career Mr Reh held positions at a government research lab, where he led teams in the design and development of life support devices; and was a lecturer at the University of Pennsylvania.

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Agenda - 15th Nov

  • 8:00am
    Registration and Networking
  • 9:00am
    Opening Remarks from the Chair

    David Crow, Senior US Business Correspondent,  Financial Times

  • 9:05am
    Keynote Opening Address

    Olivier Brandicourt, Chief Executive Officer, Sanofi

  • 9:25am
    Panel: Future Industry Business Models: Diversification vs. Pure Play

    Pharmaceutical companies have developed a number of diverse strategies to position themselves for growth and handle the challenges they face in the years ahead. Many have favoured the more traditional approach of diversification as way of benefiting from the rewards of drug making while at the same time hedging risks. Others have favoured greater focus on R&D. Disposals of non-core assets by several big pharma groups in recent years has put the latter approach firmly in the ascendancy. Which strategy will lead to success? Is a diversified structure a source of strength or weakness for a pharma company? Should companies hedge the risks of drug development by diversifying into adjacent markets? Or is it better to focus resources on the higher-margin business of making medicines? Should they shrink to grow?  Is an R&D pure-play strategy wise in view of the risks in R&D business- continuing patent expirations, significant and growing pricing pressures from public and private payers, and the rise of generics and biosimilars, for instance? Will the pendulum swing back in favour of diversification if economic prospects diminish?

    Albert Bourla, Group President, Innovative Health, Pfizer

    David Redfern, Chief Strategy Officer, GlaxoSmithKline

    Steve Wooding, Head, Global Commercial Organisation, Janssen

    Lisa Urquhart, Editor, EP Vantage

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:10am

    Lord Prior of Brampton, Parliamentary Under-Secretary of State for Health

  • 10:30am
    Networking Coffee Break
  • 10:45am
    Panel: Navigating the Shift to Value: Is Population Management the Greatest Threat or Opportunity for Pharma?

    Life Science companies are navigating a profound transformational shift as the concept of value and outcomes-based care gains traction in healthcare systems around the world. Health Technology Assessment (HTA) is becoming an established feature of healthcare landscape in Europe.  In the US, Accountable Care Organisations (ACOs) are proliferating, and an estimated 40% of healthcare dollars are now in some way tied to value. And emerging markets are also transitioning towards outcome-based models. For life science companies, the implications are profound, presenting opportunities to tap into new revenue streams associated with healthcare delivery, but also significant challenges in the transition from a product-driven industry to one focused on product-service offerings delivered in tandem with multiple stakeholders from the world of IT and data, retail, health and wellness. How are life science companies navigating the new terrain? How can life science companies ensure they remain relevant and avoid being commoditised in the new outcomes based world where data acumen, capabilities, insight, as well as patient centricity and adherence is king?

    Greg Rossi, Director Oncology Business Unit; Director, AstraZeneca UK Marketing Company

    Clare Maloney, Clinical Strategy Director, Europe, Atlantis Healthcare

    Adam Plich, Vice President, Pricing  & Market Access , Teva Pharmaceuticals Europe 

    Anant Jani, Honorary Research Fellow, Oxford University; Consultant, NHS Right Care

    Moderator: Greg Reh, Global Life Sciences Sector Leader, Deloitte

  • 11:35am
    Brexit:Thriving in a New Landscape

    The recent decision by a majority of UK citizens to leave the EU has unleashed a period of turbulence for the healthcare and life sciences industries, with the road ahead uncertain. How will Brexit play out in the months and years ahead? What will be the impact and the repercussions–direct and indirect- for the industry in the UK, Europe and beyond? What will it mean for regulation investment, innovation and patient access? How can the government and industry ensure the UK maintains its lead in science and medical research? What could constitute an effective industry roadmap for Brexit?

    Eliot Forster, CEO, Immunocoreand Chairman, MedCity

  • 11:55am
    Keynote Address

    Steve Cutler, Chief Operating Officer, ICON

  • 12:15pm
    Keynote Address

    Sir Andrew Witty, Chief Executive Officer, GlaxoSmithKline

  • 12:35pm
  • 1:45pm
    Facing the Tidal Wave: De-risking Pharma and Creating Value for Patients

    The diseases countries face are changing, with an increasing prevalence of cancer, dementia and diabetes. This, together with the rapid evolution of medical science is creating the need for new models of healthcare based on personalised medicine and behavioural science. As a result, Life Sciences companies are facing profound strategic choices on how to capture more value from their medical interventions and how to fundamentally de-risk their business models.

    Mike Standing,  EMEA Life Sciences and Healthcare Lead, Deloitte

  • 2:05pm
    Communicating Value-Financiers and Investor Perspectives
    • How should shareholder and financiers expectations be modified given the transformational changes facing the industry, particularly regarding the transition to value?
    • How should life science companies communicate business strategy for growth and value?
    • Investment strategies: dividend vs M&A?
    • Are current business models sustainable?
    • Are shareholder demands undermining the long-term productivity of R&D?

    Session Keynote: Philipp Gutzwiller, Global Head of Healthcare, Lloyds Banking Group

    Neil Woodford CBE, Head of Investment, Woodford Investment Management

    Anne Marieke Ezendam, Senior Equity Portfolio Manager, Amundi Asset Management

    Daniel Mahony, Partner-HealthcarePolar Capital

    Chris Silva, Chief Executive Officer, Allied Minds

    Moderator: Andrew Jack, Head of Curated Content, Financial Times

  • 2:55pm
    Networking Coffee Break
  • 3:10pm
    FT Keynote Interview

    Luc Debruyne, President, Global Vaccines, GlaxoSmithKline in conversation with David Crow

  • 3:30pm
    Panel: Getting Drugs to Patients Faster-Accelerating R&D

    Drug discovery and development continues to be an extremely complex, costly and lengthy process We need the pace to increase, and novel approaches to both R&D and clinical trials ,as well a greatly enhanced collaboration (between pharma companies, with academia, with regulators, CROs and across the healthcare spectrum)  if drugs are to become more accessible and affordable for patients. Drug companies have been collaborating at an unprecedented scale-recent pledges and initiatives on AMR, Alzheimer’s and the Cancer Moonshot initiatives are indicative of the wider trend, but is the industry really prepared to loosen it shackles to fully engage in these cross-industry, cross-sector initiatives? How much is posturing, and how much represents real change? Can IP and other challenges to open collaboration be effectively addressed? What role will adaptive licensing play in closing the gap between innovation and access?  Adaptive trials. risk based monitoring as well as ‘big data’ capabilities and analytics are transforming the typically outsourced clinical trial landscape. What are the novel approaches to R&D and clinical trials which can lead to faster, and better cures?

    Hervé Hoppenot, CEO, Incyte 

    Adityo Prakash, Co-Founder and Chief Executive Officer, Verseon

    Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA)

    Colin Orford, VP Product Development, ICON

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 4:20pm
    A New Era of Personalised Medicine?

    Some 15 years after the sequencing of the human genome, has the era of personalised medicine finally arrived? Are we finally entering an era of preventative, predictive, personal and participatory care? When will we see targeted medicine arrive in volume/making a measurable impact at the clinical level, with genetic medicine a mainstay and universal feature of clinical diagnosis and disease management? To what extent are payers, providers, systems, physicians and patients ready for the change? How will digital technologies and solutions play into the vision of personalised medicine? What are the remaining challenges in making the vision of personalised medicine a reality?

    Sir John Chisholm, Executive Chair, Genomics England 

    Rudi Pauwels, Chief Executive Officer, Biocartis

    Ruth March, VP and Head Personalised Healthcare & Biomarkers, AstraZeneca

    Keith Stewart, Director, Center for Individualized Medicine, Mayo Clinic

    Richard Barker, Chairman, Precision Medicine Catapult

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 5:10pm
    Closing Remarks from the Chair
  • 5:15pm
    Networking Drinks Reception

Agenda - 16th Nov

  • 8:00am
    Registration and Networking
  • 9:00am
    Opening Remarks from the Chair

    Greg Reh, Global Life Sciences Sector Leader, Deloitte

  • 9:05am
    Keynote Address

    Lars Rebien Sørensen, President and Chief Executive Officer, Novo Nordisk

  • 9:30am
    Pharma in The World’s Growth Markets

    Emerging Markets account for 75% of the world’s land mass, 60% of the global economy and will represent 85% of the total world population by 2050. With evolving economies and healthcare systems, the countries and regions that make up the Emerging Markets are also home to millions of people without access to the healthcare, diagnosis and treatment they need. This session looks at adding value to these regions from two angles. The first is Access to Medicines, where we discuss what pharmaceutical and life science companies are doing to break down barriers to access in these geographies, ensuring that improvements to healthcare can also reach countries with less developed healthcare systems. The second is a look at growth prospects. With decelerating growth in China, FX volatility and political upheaval, industry watchers have pointed to this apparent economic slowdown as a cause for concern for life science companies. How are these companies rethinking their emerging market strategies in view of this current turmoil? What are the prospects for emerging market economies and growth?

    Habil Khorakiwala, Founder-Chairman, Wockhardt 

    Jayasree K. Iyer, Executive Director, Access to Medicine Index

    Samantha Du, Founder,Chairman and Chief Executive Officer, Zai Lab

    Isabel Torres, Global Head , Access to Medicine, Takeda Pharmaceuticals International

    Onno Schellekens, Chief Executive Officer, PharmAccess Group

    Moderator: Andrew Jack, Head of Curated Content, Financial Times

  • 10:30am
    Networking Coffee Break
  • 10:50am
    The Future Commercial Models of Pharma

    Life science companies are facing the prospect of selling into an ever more challenging healthcare environment. Patients are becoming more informed and their expectations of healthcare are rising; new, ever larger customers in the shape of healthcare delivery organisations are being established as consolidation and new integrated care structures take hold; regulators and patients continue to questions the sales and marketing practices of life science companies,  and personalised medicines are upending the traditional  mass market marketing approach to product sales, requiring an ever more personalised marketing approach. What are implications of these changes for the commercial models of life science companies? What are the potential breakthrough, high-impact and innovative commercial models? What’s working and not working in the new commercial models, incentives and performance metrics which are emerging? What is the role, experience and ROI of digital marketing in the industry? How should marketeers approach the new era of personalised, evidence/value driven medicine?

    Laurie Olson, Executive Vice President, Strategy, Portfolio and Commercial Operations, Pfizer

    Emmanuel Blin, Chief Strategy Officer, Bristol-Myers Squibb

    Michel Vounatsos, Executive Vice President, Chief Commercial Officer, Biogen

    Moderator: Greg Reh, Global Life Sciences Sector Leader, Deloitte

  • 11:40am
    Digital Health-Moving the Needle?

    Too costly, too diverse, too fragmented and too app dominated-current perceptions y are barriers to the industry’s ability to achieve its longer-term potential. The future of the industry-and the ability to attract investment lies with digital innovations that can have a meaningful and measurable impact on costs and on patient health on a system wide basis. How far are we from achieving this objective, and what needs to change to make this happen?

    Jessica Federer, Head of Digital Development, Bayer

    Randall Moore, President, Mercy Virtual

    Stefani Klaskow, Head of Industry, Healthcare, Google

    Harpreet Sood, Associate Chief Clinical Information Officer, NHS England

    Nooman Haque, Director, Healthcare & Life Science, Silicon Valley Bank

    Moderator: Greg Reh, Global Life Sciences Sector Leader, Deloitte


  • 12:40pm
    Closing remarks from the Chair

Why Attend?

  • Review the diverse strategies life science companies are adopting to position themselves for growth and to navigate the emerging value and outcomes terrain
  • Debate the potential to greater cross-industry and cross-sector collaboration in the race for faster, cheaper, better cures
  • Hear from those who are turning the vision of personalised medicine into a clinical reality for patients today, and their views on the challenges ahead
  • Discover how leading life science companies are managing economic uncertainty to capitalise on the value of high-potential emerging markets
  • Gain critical insights in to new commercial models of pharma - what’s working and not working as value and personalisation upend traditional sales and marketing models
  • Don’t get left behind - be part of a must-attend event mapping the continued transformation of healthcare

Who Attends?

FT Live has a reputation for delivering very senior board level audiences to attend a wide range of world class thought-leadership events across the globe for nearly 40 years.

The FT Global Pharmaceutical and Biotechnology Conference will be attended by:

  • Pharmaceutical companies
  • Biotechnology companies
  • Diagnostic and medical devices
  • CROs
  • Healthcare providers and insurers
  • Government healthcare departments, HTA’s and drug regulators
  • Digital health companies
  • Genomics and personalised medicine experts
  • IT, big data and analytics providers
  • Health economists
  • Healthcare investment bankers, private equity and venture capitalists
  • Healthcare lawyers and management consultants
  • Patient representatives and NGOs

With the support of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit or email

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Lead Sponsors (2)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. For further information please visit  Follow @iconplc on Twitter.

GSK is a science-led global healthcare company committed to improving the quality of human life by enabling people to do more, feel better and live longer. We have three world-leading businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We are committed to widening access to our products, so more people can benefit, no matter where they live in the world or what they can afford to pay. Find out more at

Associate Sponsors (2)

Lloyds Bank Commercial Banking provides comprehensive expert financial services to businesses of all sizes, from small businesses, through to mid-sized businesses and multinational corporations.

These clients range from privately-owned firms to FTSE 100 PLCs, multinational corporations and financial institutions. 

Maintaining a network of relationship teams across the UK, as well as internationally, Lloyds Bank Commercial Banking delivers the mix of local understanding and global expertise necessary to provide long-term support to its clients.

Lloyds Bank Commercial Banking offers a broad range of finance beyond just term lending and this spans debt capital market funding, trade finance, securitisation facilities and working capital management solutions.  Its product specialists provide bespoke financial solutions including cash management, international trade, treasury and risk management services.’

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry.  We help our clients make high value decisions through superior quality, timely, must-have data, insights, combined with personalised, expert client support.

Our online subscription services cover the pharmaceutical, biotech and medtech sectors.

EP Vantage our independent, award-winning editorial team offers data-driven, forward-looking news, commentary and analysis on a daily basis.

EvaluatePharma® delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

EvaluateMedTech® sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

EvaluateClinical Trials® delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

Supporting Partners (3)

BioPharm Insight is the definitive guide to the global life sciences community. BioPharm Insight provides clients with an information edge by combining a comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists. More info at:

MedTech Europe is an alliance of European medical technology industry associations. The Alliance was founded by EDMA, representing the European in vitro diagnostic industry, and Eucomed, representing the European medical devices industry. Other European medical technology associations are welcome to join the Alliance, established to represent the common policy interests of its members more effectively and efficiently.
Our mission is to make value-based, innovative medical technology available to more people, while supporting the transformation of healthcare systems onto a sustainable path. We promote a balanced policy environment that enables the medical technology industry to meet the growing healthcare needs and expectations of its stakeholders. In addition, we demonstrate the value of medical technology by encouraging our members to execute the industry’s 5-year strategy.

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 40 leading pharmaceutical companies, EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. 

Media Partners (2)

Established in 1986, the Pharmafocus brand continues to be the most read and respected news portal in the pharmaceutical and biotech industry, with a team of dedicated journalists constantly updating the website;, monthly newspaper Pharmafocus and daily e-newsletters with the latest quality global news, thoroughly researched analysis, market intelligence and high profile interviews.  Covering important issues affecting the industry from the early stages of drug development, clinical trials, manufacturing, market access and global logistics.’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 






Marriott Grosvenor Square
Grosvenor Square
(Entrance on Duke Street)
London W1K 6JP

United Kingdom

Tel: +44 (0) 20 7499 6363


2016 Photos

To view the full set of the conference photographs please click here

FT Global Pharmaceutical and Biotechnology Conference   Flickr



For accommodation options located near the venue, please click here.

Book your group rate for Financial Times ref Pharma Bio

Alternatively your guests can call our reservations team on: 0800 221 222 and Quote: L1VA as a special group code


Contact us

Aneliese Hirst
Media Partner And Press Enquiries
Financial Times
Angela Letinov
Speaking Opportunities
Financial Times
Joe Hames
Sponsorship Opportunities
Financial Times
Zowie Fort
Delegate Booking and Registration Enquiries